Is MetLife Outperforming the Nasdaq?

Is MetLife Outperforming the Nasdaq?

Mon, September 7, 2026 at 3:20 PM GMT+3 2 min read

• MET -2.17%
• ^IXIC -0.32%

MetLife, Inc. (MET), headquartered in New York, is a global insurance and financial services company operating through subsidiaries and affiliates, with a market capitalization of $62.8 billion. The company holds leading market positions across the U.S., Japan, Latin America, Asia, Europe, the Middle East, and Africa, serving customers through diverse insurance and financial solutions.

Companies valued between $10 billion and $200 billion are generally classified as "large-cap stocks," and MetLife comfortably fits this category. Its substantial market capitalization reflects its size, influence, and established position within the life insurance industry. MetLife benefits from a strong market presence and trusted brand across the U.S., Asia, and Latin America. Its geographic diversification helps reduce reliance on any single market, while a robust balance sheet, consistent revenue streams, and prudent investment and risk management support its financial resilience.

More News from Barchart

MET has slipped 3.3% from its 52-week high of $100.93, reached on August 6, 2026. Over the past three months, MET stock has climbed 17%, significantly outpacing the Nasdaq Composite ($NASX), which declined 1.2% over the same period.

Shares of MET have gained 22.5% year to date and 32.6% over the past 52 weeks, outperforming the Nasdaq Composite's 14.4% year-to-date gain and 23.7% return over the past year.

MET has traded above its 50-day moving average since early April and above its 200-day moving average since late April, indicating sustained upward momentum.

MetLife has outpaced the broader market over the past year, potentially supported by strong operating performance and broad-based growth. In its second-quarter 2026 results, the company reported a 15.5% increase in adjusted earnings to $1.57 billion, while adjusted earnings per share rose 20.3% to $2.43. Premiums, fees and other revenues increased 7% to $13.7 billion, driven by favorable underwriting and volume growth.

Within the competitive healthcare plans industry, top rival Aflac Incorporated (AFL) has slightly underperformed MET, gaining 6.3% year-to-date and 8% over the past 52 weeks.

Wall Street analysts are bullish on MET's prospects. The stock carries a consensus "Moderate Buy" rating from the 19 analysts covering it. Moreover, the mean price target of $106.23 implies an 8.8% premium to its current price.

On the date of publication, Kritika Sarmah did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Barchart.com